Company profile

Paolo Pucci
Incorporated in
Fiscal year end
IRS number

ARQL stock data



30 Oct 19
30 May 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 208K 281K 1.35M
Net income -10.74M -9.09M -10.27M -8.49M
Diluted EPS -0.09 -0.08 -0.1 -0.08
Net profit margin -5163% -3236% -763%
Operating income -11.28M -9.22M -10.4M -8.65M
Net change in cash -66.49M 90.86M -1.41M 3.06M
Cash on hand 42.2M 108.69M 17.82M 19.24M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Net income -15.48M -29.2M -22.72M -13.77M
Diluted EPS -0.16 -0.39 -0.33 -0.22
Operating income -13.7M -27.02M -22.9M -14.15M
Net change in cash -993K 4.96M 1.28M 1.46M
Cash on hand 19.24M 20.23M 15.27M 13.98M

Financial data from Arqule earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
16 Jan 20 Susan L. Kelley Stock Option Common Stock Sale back to company Dispose D 1.8 15,000 27K 0
16 Jan 20 William G Messenger Common Stock Dispose U 20 20,000 400K 0
16 Jan 20 William G Messenger Stock Option Common Stock Sale back to company Dispose D 1.23 20,000 24.6K 0
16 Jan 20 William G Messenger Stock Option Common Stock Sale back to company Dispose D 1.68 20,000 33.6K 0
16 Jan 20 William G Messenger Stock Option Common Stock Sale back to company Dispose D 1.8 15,000 27K 0
16 Jan 20 William G Messenger Stock Option Common Stock Sale back to company Dispose D 1.42 15,000 21.3K 0
16 Jan 20 William G Messenger Stock Option Common Stock Sale back to company Dispose D 2.78 15,000 41.7K 0
16 Jan 20 William G Messenger Stock Option Common Stock Sale back to company Dispose D 5.82 15,000 87.3K 0
16 Jan 20 William G Messenger Stock Option Common Stock Sale back to company Dispose D 6.71 15,000 100.65K 0
16 Jan 20 William G Messenger Stock Option Common Stock Sale back to company Dispose D 6.14 15,000 92.1K 0
93.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 197 162 +21.6%
Opened positions 88 28 +214.3%
Closed positions 53 34 +55.9%
Increased positions 51 64 -20.3%
Reduced positions 39 43 -9.3%
13F shares
Current Prev Q Change
Total value 2.26B 646.09M +250.5%
Total shares 113.38M 90.12M +25.8%
Total puts 3.64M 508.8K +614.7%
Total calls 7.66M 2.79M +174.6%
Total put/call ratio 0.5 0.2 +160.3%
Largest owners
Shares Value Change
BLK BlackRock 10.01M $199.79M +2.4%
Consonance Capital Management 6.72M $134.05M +67.4%
Nantahala Capital Management 6.54M $130.63M -34.9%
Vanguard 5.92M $118.12M +2.4%
Orbimed Advisors 5M $99.8M +35.1%
STT State Street 4.22M $84.16M -32.0%
Citadel Advisors 3.31M $65.98M +4054.3%
BVF 2.98M $59.46M +41.3%
GS Goldman Sachs 2.97M $59.19M +194.3%
JPM JPMorgan Chase & Co. 2.76M $55.15M +7412.2%
Largest transactions
Shares Bought/sold Change
Nantahala Capital Management 6.54M -3.52M -34.9%
Citadel Advisors 3.31M +3.23M +4054.3%
Alkeon Capital Management 0 -3.1M EXIT
Bleichroeder 2.75M +2.75M NEW
JPM JPMorgan Chase & Co. 2.76M +2.73M +7412.2%
Consonance Capital Management 6.72M +2.7M +67.4%
Farallon Capital Management 2.52M +2.52M NEW
Magnetar Financial 2.39M +2.39M NEW
Candriam Luxembourg S.C.A. 224.04K -2.28M -91.1%
Alpine Associates Management 2.12M +2.12M NEW

Financial report summary

  • Our product candidates are in preclinical and clinical stages of development and we may not successfully develop a product candidate that becomes a commercially viable drug.
  • We must show the safety and efficacy of our product candidates through expensive, time consuming preclinical testing and clinical trials, the results of which are uncertain and governed by exacting regulations.
  • Delays in clinical testing could result in increased costs to us and delay our ability to obtain regulatory approval and commercialize our product candidates.
  • The results of early-stage clinical trials and preclinical studies may not be predictive of future results. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.
  • If serious adverse events or undesirable side effects are identified during the development of any product candidates we may develop, we may need to abandon or limit our further clinical development of those product candidates.
  • If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented.
  • Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics could harm our drug development strategy.
  • We have limited clinical development and commercialization experience.
  • If our drug discovery and development programs do not progress as anticipated, our revenue and stock price could be negatively impacted.
  • Even if our product candidates obtain regulatory approval, we and our collaborators will be subject to ongoing government regulation.
  • Even if we or our collaborators bring products to market, we may be unable to price our products effectively or obtain adequate reimbursement for sales of our products, which would have an adverse effect on our revenues.
  • We have incurred significant losses since our inception and anticipate that we will incur significant continued losses for the next several years, and our future profitability is uncertain.
  • We are party to a loan and security agreement that contains operating and financial covenants that may restrict our business and financing activities.
  • We may need substantial additional funding and we may be unable to raise capital when needed, or on terms favorable to us, which could force us to delay, reduce or eliminate our drug discovery, product development and commercialization activities.
  • We have federal and state net operating loss carryforwards (“NOLs”) and research and development credit carryforwards which, if we were to become profitable, could be used to offset/defer federal and state income taxes. Such carryforwards may not, under certain circumstances related to changes in ownership of our stock, be available to us.
  • Comprehensive tax reform could adversely affect our business and financial condition.
  • Part of our business strategy involves collaborative out-licensing of our product candidates. We may not be able to find collaborators or successfully form suitable collaborations to further our drug development and commercialization efforts.
  • Our success depends in part on the efforts of our current and possible future collaborators, who will likely have substantial control and discretion over the continued development and commercialization of product candidates that are the subjects of our collaborations.
  • We rely heavily on third parties such as contract research organizations, to conduct our nonclinical studies and clinical trials. If third parties upon which we rely do not perform as contractually required or expected, we may not be able to develop further, obtain regulatory approval for or commercialize our product candidates.
  • We rely on third parties to manufacture sufficient quantities of our product candidates to conduct preclinical and clinical studies. We may not be able to maintain these relationships and could experience supply disruptions outside of our control.
  • The drug research and development industry is highly competitive, and we compete with some companies that have a broader range of capabilities and better access to resources than we do.
  • We may not be able to recruit and retain the scientists and management we need to compete.
  • Our patents may fail to protect our business. If we are unable to obtain and maintain patent protection for our product candidates or if the scope of the patent protection obtained is not sufficiently broad, third parties may be able to develop and commercialize technology and products similar or identical to ours, which could adversely affect our ability to compete in the market.
  • We only have limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.
  • The drug research and development industry has a history of patent and other intellectual property litigation, and we may be involved in costly intellectual property lawsuits.
  • Agreements we have with our employees, consultants and collaborators may not afford adequate protection for our trade secrets, confidential information and other proprietary information.
  • We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
  • We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent offices, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If we are not able to obtain patent term extensions in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product candidates, our business may be impaired.
  • We face potential liability related to the privacy of health information.
  • We may be exposed to potential liability related to the development, testing or manufacturing of compounds we develop and our insurance coverage may not be sufficient to cover losses.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business.
  • We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Our operations could be interrupted by damage to our laboratory facilities.
  • Security breaches may disrupt our operations and adversely affect our operating results.
  • Our stock price may be extremely volatile.
  • Some of our existing stockholders can exert control over us, and their interests could conflict with the best interests of our other stockholders.
  • Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management.
  • Because we do not intend to pay dividends, stockholders will benefit from an investment in our common stock only if it appreciates in value.
Content analysis ?
H.S. junior Avg
New words: null, resultedin, scheduled
Removed: dated, iii, requiring, thousand


Pharmaceutical Combination for Treatment of Cancer
21 May 20
The present application is drawn to methods of treating a cell proliferative disorder, such as a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising at least one of Compound 1, Compound 2, and Compound 3, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and at least one second therapeutic agent or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the cell proliferative disorder is treated.
Solid Forms of Tetrahydropyranyl Amino-pyrrolopyrimidinone Compounds
7 May 20
The present application provides solid forms of (2-chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone free base, and methods of preparing and using the same.
Methods for Preparing Substituted 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE
2 Apr 20
Inventors: Craig BATES, Jianmin MAO, David P. REED
Tetrahydropyranyl Amino-pyrrolopyrimidinone and Methods of Use Thereof
27 Feb 20
Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
Solid Forms of Substituted 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE Compounds
2 Jan 20
The present application provides solid forms of (R)-6-(2-fluorophenyl)-N-(3-(2-(2-methoxyethylamino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride, and methods of preparing and using same.